Molecular Formula | C23H33NO7S2
|
Molar Mass | 499.64062 |
Melting Point | 84-87°C |
Solubility | DMSO: >20mg/mL |
Appearance | powder |
Color | white to off-white |
Merck | 14,9003 |
Storage Condition | Inert atmosphere,Room Temperature |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months. |
Physical and Chemical Properties | Melting point 84-87°C |
In vitro study | Suplatast tosilate acts on isolated mouse spleen and human peripheral blood B cells to inhibit antibody production with IC50>100 nM. Suplatast tosilate inhibits cytokine production in mice and humans, IFN-γ, IL-2, IL-4, IL-5 and IL-10,IC50>100 nM. Suplatast tosilate (1 and 10 µg/ml) inhibited SN-4-induced cryj1-dependent IgE synthesis in autologous B cells in a concentration-dependent manner. Suplatast tosilate (1 and 10 µg/mL) effectively inhibited IL-4 production in a concentration-dependent manner. In the presence of autologous APC, SN-4 and Cryj1 stimulated IL-4 production for 3 days, normal donor-supplied PHA-stimulated PBMC produced IL-4. Suplatast tosilate significantly inhibited CD1a, CD80, and CD86 expression in immature dendritic cells and significantly inhibited CD1a, CD80, CD83, and CD86 expression in mature dendritic cells (DCs). Suplatast tosilate also significantly inhibited CCL17, IL-12p70, and IL-12p40 secretion, yet did not affect IL-10 secretion. DCs treated with Suplatast tosilate inhibited allogeneic CD4 ( |
In vivo study | Suplatast tosilate (100 mg/kg/100 µl), acting on BALF, significantly reduced total cell number, and eosinophil number, almost completely inhibited antigen-induced BHR development. Pathological results confirmed that the mucosal cell invasion in the lung was reduced and the bronchial epithelial cell injury was significantly inhibited. The specific IgE of ovalbumin was significantly reduced, but not much. Suplatast tosilate-treated mice had significantly lower IL-4, IL-5, and IL-13 in BALF compared to control mice without treatment. |